Pharmacoeconomic review report. Empagliflozin (Jardiance).
Empagliflozin (Jardiance) is a once-daily oral antidiabetic drug belonging to the sodium glucose cotransporter-2 (SGLT-2) inhibitor class. It promotes urinary glucose excretion. This review by the CADTH Common Drug Review (CDR) will focus on the following indication: 1. For adults with type 2 diabet...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK533798/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
CADTH,
2015
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
| Summary: | Empagliflozin (Jardiance) is a once-daily oral antidiabetic drug belonging to the sodium glucose cotransporter-2 (SGLT-2) inhibitor class. It promotes urinary glucose excretion. This review by the CADTH Common Drug Review (CDR) will focus on the following indication: 1. For adults with type 2 diabetes mellitus, to improve glycemic control in combination with metformin and a sulfonylurea when diet, exercise, and dual therapy (with metformin plus sulfonylurea) do not provide adequate glycemic control. The recommended dose of empagliflozin is 10 mg once daily. This dose can be increased to 25 mg once daily in patients who tolerate empagliflozin but need additional glycemic control. The manufacturer submitted a price of $2.6177 per 10 mg or 25 mg tablet ($2.62 daily). The manufacturer is requesting a listing in a manner similar to other SGLT-2 inhibitors and/or dipeptidyl peptidase (DPP)-4 inhibitors. |
|---|---|
| Physical Description: | 1 online resource (1 PDF file (ii, 13 pages)). |
| Bibliography: | Includes bibliographical references. |
| Source of Description, Etc. Note: | Description based on online resource; title from PDF title page (viewed February 6, 2019). |
| Funding Information Note: | Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. |
